Tris Pharma Settled Claims Over ADHD Drug Marketing
The manufacturer agreed to pay $7.5 million to resolve allegations that it misled Medicaid providers about drug efficacy.
Updated on Oct. 1, 2026 in Healthcare
Live Poll
Should pharmaceutical companies face financial penalties for making misleading drug marketing claims?
Tris Pharma has reached a $7.5 million settlement with Texas and a whistleblower to resolve allegations that the company misrepresented the efficacy of its ADHD medication, Dyanavel XR. The state claimed that sales representatives incorrectly told providers that the drug worked faster than competing treatments.
Why it matters
The settlement underscores the high legal and operational risks involved in medical sales communication, particularly when marketing to state-funded programs like Medicaid. Companies must ensure that efficacy claims for pediatric medications are strictly aligned with approved clinical data to avoid significant regulatory and financial liabilities.
Tris Pharma agreed to pay $7.5 million to resolve claims from Texas and a whistleblower regarding the marketing of its ADHD drug, Dyanavel XR. This settlement concludes allegations that the firm misrepresented product performance to pediatric Medicaid providers.
The players
Tris Pharma
A pharmaceutical company that specializes in the development and marketing of attention-deficit/hyperactivity disorder medications for children.
Ketan Mehta
The CEO of Tris Pharma who oversaw the company during the period of the alleged marketing misconduct.
The details
The state of Texas alleged that Tris Pharma directed its sales representatives to provide misleading information to physicians about how quickly Dyanavel XR functioned compared to competing ADHD medications. By marketing these performance advantages, the company allegedly influenced prescribing patterns within the Medicaid program. Tris Pharma and CEO Ketan Mehta have officially denied any wrongdoing in relation to these marketing practices.
Timeline
September 24, 2026: The Texas Attorney General announced the settlement.
October 1, 2026: Article publication date.
Market Landscape
This settlement follows a long-standing pattern of enforcement actions under the False Claims Act regarding the accuracy of representations made to state-funded healthcare providers. It highlights the continued scrutiny pharmaceutical firms face when marketing to public Medicaid programs.
Operators in the pharmaceutical and medical sales space should audit their sales training materials to ensure all claims regarding drug performance are substantiated by clinical data. Legal and compliance teams must verify that marketing communications directed at Medicaid providers strictly mirror approved product labels.
The takeaway
Misleading marketing claims can lead to substantial financial settlements that impact firm valuation and regulatory standing. Leaders should mandate periodic reviews of all field-level sales scripts to ensure they align with objective product efficacy data.
Further reading
For more on industry compliance, see our reporting on Healthcare.
Live Poll
Should pharmaceutical companies face financial penalties for making misleading drug marketing claims?
